<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707445</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC-GENIUS</org_study_id>
    <nct_id>NCT02707445</nct_id>
  </id_info>
  <brief_title>Genotyping Influences Outcome of Coronary Artery Stenting</brief_title>
  <acronym>GENIUS</acronym>
  <official_title>Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated epidemiology and clinical outcome of clopidogrel related various
      genotyping in Korean patients who had undergone percutaneous coronary intervention as a all
      comer registry form.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the relationship between clopidogrel related various genotyping,
      epidemiology and clinical outcome of patient who had undergone percutaneous coronary
      intervention. Clopidogrel resistance was measured with VerifyNow, which is a device that can
      monitor platelet inhibition of clopidogrel. Genes which are known to be related with
      clopidogrel resistance were evaluated; (1-3) CYP 2C19 *2, *3, *17, (4) PON1 Q192R, (5) ABCB1
      3435C-&gt;T, (6) P2Y12, (7) CYP 2C9 *3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarction and Death</measure>
    <time_frame>1 year after index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any death</measure>
    <time_frame>1 year after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 year after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (acute, late, very late)</measure>
    <time_frame>1 year after index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 year after index procedure</time_frame>
    <description>Revascularization of in-stent restenosis which developed in previously implanted stent on index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year after index procedure</time_frame>
    <description>Ischemic or hemorrhagic cerebral infarction diagnosed by brain MRI which developed within 1 year after index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complication</measure>
    <time_frame>During index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRU</measure>
    <time_frame>Within index procedure</time_frame>
    <description>Value which is measured with VerifyNow that can monitor platelet inhibition of clopidogrel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARU</measure>
    <time_frame>Within index procedure</time_frame>
    <description>Value which is measured with VerifyNow that can monitor platelet inhibition of aspirin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5000</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>CLOPIDOGREL, POOR METABOLISM of (Disorder)</condition>
  <arm_group>
    <arm_group_label>GENIUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention</description>
    <arm_group_label>GENIUS</arm_group_label>
    <other_name>clopidogrel hydrogen sulfate 97.875mg (75mg as clopidogrel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Older than 20 years

          -  All percutaneous coronary intervention patients within 1 month

        Exclusion Criteria:

          -  Pregnancy

          -  Life expectancy below 1 year

          -  Known aspirin or clopidogrel allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do-sun Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular center, Korea University Anam Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 1990 Sep;82(3 Suppl):II47-59. Review.</citation>
    <PMID>2203564</PMID>
  </results_reference>
  <results_reference>
    <citation>Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001 Nov;12(7):443-7.</citation>
    <PMID>11674863</PMID>
  </results_reference>
  <results_reference>
    <citation>Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16. Epub 2007 Mar 26. Review.</citation>
    <PMID>17418288</PMID>
  </results_reference>
  <results_reference>
    <citation>Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010 Oct;31(20):2501-55. doi: 10.1093/eurheartj/ehq277. Epub 2010 Aug 29.</citation>
    <PMID>20802248</PMID>
  </results_reference>
  <results_reference>
    <citation>Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 May 10;57(19):1920-59. doi: 10.1016/j.jacc.2011.02.009. Epub 2011 Mar 28. Erratum in: J Am Coll Cardiol. 2011 May 10;57(19):1960.</citation>
    <PMID>21450428</PMID>
  </results_reference>
  <results_reference>
    <citation>Schömig A. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? N Engl J Med. 2009 Sep 10;361(11):1108-11. doi: 10.1056/NEJMe0906549. Epub 2009 Aug 30.</citation>
    <PMID>19717845</PMID>
  </results_reference>
  <results_reference>
    <citation>Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.</citation>
    <PMID>19106083</PMID>
  </results_reference>
  <results_reference>
    <citation>Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.</citation>
    <PMID>20978260</PMID>
  </results_reference>
  <results_reference>
    <citation>Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19. Erratum in: Nat Med. 2011 Sep;17(9):1153.</citation>
    <PMID>21170047</PMID>
  </results_reference>
  <results_reference>
    <citation>Gladding P, White H, Voss J, Ormiston J, Stewart J, Ruygrok P, Bvaldivia B, Baak R, White C, Webster M. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. JACC Cardiovasc Interv. 2009 Nov;2(11):1095-101. doi: 10.1016/j.jcin.2009.08.018.</citation>
    <PMID>19926050</PMID>
  </results_reference>
  <results_reference>
    <citation>Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003 Aug 26;108(8):989-95. Epub 2003 Aug 11.</citation>
    <PMID>12912815</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006 Jul;80(1):33-40. Epub 2006 Jun 8.</citation>
    <PMID>16815315</PMID>
  </results_reference>
  <results_reference>
    <citation>Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G&gt;A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.</citation>
    <PMID>18482659</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Do-sun Lim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

